Deep learning-based approach for automated assessment of PTEN status.

Abstract

294 Background: PTEN loss is associated with adverse outcomes in prostate cancer and has the potential to be clinically implemented as a prognostic biomarker. Deep learning algorithms applied to digital pathology can provide automated and objective assessment of biomarkers. The objective of this work was to develop an artificial intelligence (AI) system for automated detection and localization of PTEN loss in prostate cancer samples. Methods: Immunohistochemistry (IHC) was used to measure PTEN protein levels on prostate tissue microarrays (TMA) from two institutions (in-house n=272 and external n=125 patients). TMA cores were visually scored for PTEN loss by pathologists and, if present, spatially annotated. In-house cohort (N=1239 cores) were divided into 70/20/10 training/validation/testing sets. Two algorithms were developed: a) Class I=core-based, to label each core for biomarker status and b) Class II=pixel-based, to spatially distinguish areas of PTEN loss within each core. ResNet101 architecture was used to train a multi-resolution ensemble of classifiers at 5x, 10x, and 20x for Class I task and a single classifier at simulated 40x for Class II segmentation. Results: For Class I algorithm, accuracy of PTEN status was 88.3% and 93.4% in validation and testing cohorts, respectively (Table). AI-based probability of PTEN loss was higher in cores with complete loss vs partial loss. Accuracy was improved to 90.7% in validation and 93.5% in test cohorts using the Class II region-based algorithm, with median dice scores 0.833 and 0.831, respectively. Direct application to external set demonstrated a high false positive rate. Loading trained model and conservatively re-training (“fine-tuning”) on 48/320 external cohort cores improved accuracy to 93.4%. Conclusions: Results demonstrate feasibility and robustness for fully automated detection and localization of PTEN loss in prostate cancer tissue samples and possibility for time/cost-effectiveness of sample processing/scoring in research and clinical laboratories.[Table: see text]

Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation

“…Furthermore, recent innovation in digital pathology means automated scoring algorithms using continuous variables for both proliferative markers and PTEN are increasingly feasible. 24 , 42 …”

“…Historical limitations in digital pathology have also restricted innovative computational histological analysis in prostate cancer, but progress in artificial intelligence means novel automated image analysis approaches are becoming feasible. 23 , 24 , 25 …”